Critical information on the nature of the coagulation-cancer interaction has been obtained
from a number of sources. In vitro/ex vivo sources of information include assays performed …

A volume of data that has accumulated for over a century has suggested that fibrin may
facilitate the persistence and progression of malignancy. Techniques that have been …

Components of coagulation and fibrinolysis reactions were identified in situ by
immunohistochemical staining in fresh frozen sections of small cell carcinoma of the lung …

Systemic activation of the coagulation mechanism is known to exist in patients with colon
cancer. The mechanism of such activation was investigated using immunohistochemical …

Abstract Background and Methods. Fifty‐one patients with small cell lung cancer (SCLC)
were treated with alternating urokinase (UK)‐cyclophosphamide‐doxorubicin (Adriamycin …

Clinical trials of drugs that influence coagulation and fibrinolysis pathways have been
undertaken in patients with malignancy because these pathways are capable of influencing …

At the European Consensus Conference held in Windsor, UK, in November 1991, 16 a
moderate risk for the development of venous thrombosis (VT) was postulated for most …

The blood coagulation mechanism in general and the plasminogen system in particular
contribute to malignant growth and dissemination in complex ways. This article reviews the …

The Subcommittee on Hemostasis and Malignancy of the Scientific and Standardization
Committee determined at its meeting of July 8, L992, to update the registry of clinical trials of …

It is common knowledge that blood coagulation and fibrinolysis are activated systemically in
patients with malignancy. Studies in specific in vitro and animal models of malignancy have …